基本信息 产品详情 公司简介 推荐产品
网站主页 ALPHA-D-GAL-[1->4]-BETA-D-GAL-[1->4]-BETA-D-GLC-1->O-SPHINGOSINE Lyso-Globotriaosylceramide (d18:1)
  • Lyso-Globotriaosylceramide (d18:1)|T37291|TargetMol

Lyso-Globotriaosylceramide (d18:1)|T37291|TargetMol

Lyso-Globotriaosylceramide (d18:1)
15400 1mg 起订
上海 更新日期:2024-12-12

TargetMol中国(陶术生物)

VIP3年
联系人:邵小姐
手机:4008200310 拨打
邮箱:marketing@tsbiochem.com

产品详情:

中文名称:
Lyso-Globotriaosylceramide (d18:1)
英文名称:
Lyso-Globotriaosylceramide (d18:1)
CAS号:
126550-86-5
品牌:
TargetMol
产地:
美国
保存条件:
Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
产品类别:
抑制剂
货号:
T37291

Product Introduction

Bioactivity

名称Lyso-Globotriaosylceramide (d18:1)
描述Lyso-globotriaosylceramide is a form of globotriaosylceramide that is lacking the fatty acyl group. It binds to Shiga toxin 1 (Stx1) in the presence of cholesterol and phosphatidylcholine but does not bind Stx2. It also reduces viability and aggregation of human neutrophils induced by phorbol 12-myristate 13-acetate when used at concentrations of 50 and 1 μM, respectively. Lyso-globotriaosylceramide accumulates in the brain, heart, kidney, liver, lung, and spleen in a mouse model of Fabry disease, a lysosomal storage disorder characterized by a deficiency in the enzyme α-galactosidase A. It also accumulates in the urine, kidney, and plasma of patients with Fabry disease. Lyso-globotriaosylceramide levels decrease in response to administration of the α-galactosidase inhibitor 1-deoxygalactonojirimycin in a transgenic mouse model of Fabry disease. Decreases in plasma and urine concentrations of lyso-globotriaosylceramide have been used as a biomarker for efficacy of enzyme replacement therapy (ERT) and other therapies in the treatment of Fabry disease.
存储条件Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
溶解度Chloroform:Methanol:H2O (4:3:1) : Soluble
关键字LysoGlobotriaosylceramide (d18:1) | Lyso Globotriaosylceramide (d18:1) | Lyso-Globotriaosylceramide | Lyso-Globotriaosylceramide (d-18:1) | d18:1
Lyso-Globotriaosylceramide (d18:1)|TargetMol

公司简介

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿,致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区,已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库,以及多种类型的生化试剂产品,包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等,此外,我们还建设有CADD(计算机辅助药物设计)研究中心、药理实验室、药化合成平台三大技术中心,全方位满足客户的定制需求。 凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持,我们将有效帮助您缩短研发周期,取得更成功的结果。

成立日期 (12年)
注册资本 566.265100万人民币
员工人数 100-500人
年营业额 ¥ 1亿以上
经营模式 贸易,工厂,试剂,定制,服务
主营行业 天然产物,生化试剂,分子生物学,分子砌块,生物技术服务

Lyso-Globotriaosylceramide (d18:1)相关厂家报价

  • D18
  • D18
  • 河南威梯希化工科技有限公司 VIP
  • 2025-01-24
  • 询价
  • 辛烷-d18
  • 辛烷-d18
  • 陕西缔都新材料有限公司 VIP
  • 2024-12-18
  • 询价
内容声明
拨打电话 立即询价